@article{Kitchin2022,
abstract = {Summary The Janssen (Johnson {\&} Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.},
author = {Kitchin, Dale and Richardson, Simone I and van der Mescht, Mieke A and Motlou, Thopisang and Mzindle, Nonkululeko and Moyo-Gwete, Thandeka and Makhado, Zanele and Ayres, Frances and Manamela, Nelia P and Spencer, Holly and Lambson, Bronwen and Oosthuysen, Brent and Kaldine, Haajira and du Pisanie, Marizane and Mennen, Mathilda and Skelem, Sango and Williams, Noleen and Ntusi, Ntobeko A B and Burgers, Wendy A and Gray, Glenda G and Bekker, Linda-Gail and Boswell, Michael T and Rossouw, Theresa M and Ueckermann, Veronica and Moore, Penny L},
doi = {10.1016/J.XCRM.2022.100535},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Kitchin et al. - 2022 - Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS.pdf:pdf},
issn = {2666-3791},
journal = {Cell Reports Medicine},
keywords = {Ad26.COV2.S,OA,Omicron,SARS-CoV-2,Variant of concern,antibody-dependent cellular cytotoxicity,breakthrough infection,fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,original},
month = {feb},
number = {3},
pages = {100535},
pmid = {35474744},
publisher = {Elsevier},
title = {{Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern}},
url = {http://www.cell.com/article/S2666379122000350/fulltext http://www.cell.com/article/S2666379122000350/abstract https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(22)00035-0},
volume = {3},
year = {2022}
}

{"_id":"pZJiFtNFQckk4LNqy","bibbaseid":"kitchin-richardson-vandermescht-motlou-mzindle-moyogwete-makhado-ayres-etal-ad26cov2sbreakthroughinfectionsinducehightitersofneutralizingantibodiesagainstomicronandothersarscov2variantsofconcern-2022","author_short":["Kitchin, D.","Richardson, S. I","van der Mescht, M. A","Motlou, T.","Mzindle, N.","Moyo-Gwete, T.","Makhado, Z.","Ayres, F.","Manamela, N. P","Spencer, H.","Lambson, B.","Oosthuysen, B.","Kaldine, H.","du Pisanie, M.","Mennen, M.","Skelem, S.","Williams, N.","Ntusi, N. A B","Burgers, W. A","Gray, G. G","Bekker, L.","Boswell, M. T","Rossouw, T. M","Ueckermann, V.","Moore, P. L"],"bibdata":{"bibtype":"article","type":"article","abstract":"Summary The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.","author":[{"propositions":[],"lastnames":["Kitchin"],"firstnames":["Dale"],"suffixes":[]},{"propositions":[],"lastnames":["Richardson"],"firstnames":["Simone","I"],"suffixes":[]},{"propositions":["van","der"],"lastnames":["Mescht"],"firstnames":["Mieke","A"],"suffixes":[]},{"propositions":[],"lastnames":["Motlou"],"firstnames":["Thopisang"],"suffixes":[]},{"propositions":[],"lastnames":["Mzindle"],"firstnames":["Nonkululeko"],"suffixes":[]},{"propositions":[],"lastnames":["Moyo-Gwete"],"firstnames":["Thandeka"],"suffixes":[]},{"propositions":[],"lastnames":["Makhado"],"firstnames":["Zanele"],"suffixes":[]},{"propositions":[],"lastnames":["Ayres"],"firstnames":["Frances"],"suffixes":[]},{"propositions":[],"lastnames":["Manamela"],"firstnames":["Nelia","P"],"suffixes":[]},{"propositions":[],"lastnames":["Spencer"],"firstnames":["Holly"],"suffixes":[]},{"propositions":[],"lastnames":["Lambson"],"firstnames":["Bronwen"],"suffixes":[]},{"propositions":[],"lastnames":["Oosthuysen"],"firstnames":["Brent"],"suffixes":[]},{"propositions":[],"lastnames":["Kaldine"],"firstnames":["Haajira"],"suffixes":[]},{"propositions":["du"],"lastnames":["Pisanie"],"firstnames":["Marizane"],"suffixes":[]},{"propositions":[],"lastnames":["Mennen"],"firstnames":["Mathilda"],"suffixes":[]},{"propositions":[],"lastnames":["Skelem"],"firstnames":["Sango"],"suffixes":[]},{"propositions":[],"lastnames":["Williams"],"firstnames":["Noleen"],"suffixes":[]},{"propositions":[],"lastnames":["Ntusi"],"firstnames":["Ntobeko","A","B"],"suffixes":[]},{"propositions":[],"lastnames":["Burgers"],"firstnames":["Wendy","A"],"suffixes":[]},{"propositions":[],"lastnames":["Gray"],"firstnames":["Glenda","G"],"suffixes":[]},{"propositions":[],"lastnames":["Bekker"],"firstnames":["Linda-Gail"],"suffixes":[]},{"propositions":[],"lastnames":["Boswell"],"firstnames":["Michael","T"],"suffixes":[]},{"propositions":[],"lastnames":["Rossouw"],"firstnames":["Theresa","M"],"suffixes":[]},{"propositions":[],"lastnames":["Ueckermann"],"firstnames":["Veronica"],"suffixes":[]},{"propositions":[],"lastnames":["Moore"],"firstnames":["Penny","L"],"suffixes":[]}],"doi":"10.1016/J.XCRM.2022.100535","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Kitchin et al. - 2022 - Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS.pdf:pdf","issn":"2666-3791","journal":"Cell Reports Medicine","keywords":"Ad26.COV2.S,OA,Omicron,SARS-CoV-2,Variant of concern,antibody-dependent cellular cytotoxicity,breakthrough infection,fund_ack,original","mendeley-tags":"OA,fund_ack,original","month":"feb","number":"3","pages":"100535","pmid":"35474744","publisher":"Elsevier","title":"Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern","url":"http://www.cell.com/article/S2666379122000350/fulltext http://www.cell.com/article/S2666379122000350/abstract https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(22)00035-0","volume":"3","year":"2022","bibtex":"@article{Kitchin2022,\r\nabstract = {Summary The Janssen (Johnson {\\&} Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.},\r\nauthor = {Kitchin, Dale and Richardson, Simone I and van der Mescht, Mieke A and Motlou, Thopisang and Mzindle, Nonkululeko and Moyo-Gwete, Thandeka and Makhado, Zanele and Ayres, Frances and Manamela, Nelia P and Spencer, Holly and Lambson, Bronwen and Oosthuysen, Brent and Kaldine, Haajira and du Pisanie, Marizane and Mennen, Mathilda and Skelem, Sango and Williams, Noleen and Ntusi, Ntobeko A B and Burgers, Wendy A and Gray, Glenda G and Bekker, Linda-Gail and Boswell, Michael T and Rossouw, Theresa M and Ueckermann, Veronica and Moore, Penny L},\r\ndoi = {10.1016/J.XCRM.2022.100535},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Kitchin et al. - 2022 - Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS.pdf:pdf},\r\nissn = {2666-3791},\r\njournal = {Cell Reports Medicine},\r\nkeywords = {Ad26.COV2.S,OA,Omicron,SARS-CoV-2,Variant of concern,antibody-dependent cellular cytotoxicity,breakthrough infection,fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nmonth = {feb},\r\nnumber = {3},\r\npages = {100535},\r\npmid = {35474744},\r\npublisher = {Elsevier},\r\ntitle = {{Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern}},\r\nurl = {http://www.cell.com/article/S2666379122000350/fulltext http://www.cell.com/article/S2666379122000350/abstract https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(22)00035-0},\r\nvolume = {3},\r\nyear = {2022}\r\n}\r\n","author_short":["Kitchin, D.","Richardson, S. I","van der Mescht, M. A","Motlou, T.","Mzindle, N.","Moyo-Gwete, T.","Makhado, Z.","Ayres, F.","Manamela, N. P","Spencer, H.","Lambson, B.","Oosthuysen, B.","Kaldine, H.","du Pisanie, M.","Mennen, M.","Skelem, S.","Williams, N.","Ntusi, N. A B","Burgers, W. A","Gray, G. G","Bekker, L.","Boswell, M. T","Rossouw, T. M","Ueckermann, V.","Moore, P. L"],"key":"Kitchin2022","id":"Kitchin2022","bibbaseid":"kitchin-richardson-vandermescht-motlou-mzindle-moyogwete-makhado-ayres-etal-ad26cov2sbreakthroughinfectionsinducehightitersofneutralizingantibodiesagainstomicronandothersarscov2variantsofconcern-2022","role":"author","urls":{"Paper":"http://www.cell.com/article/S2666379122000350/fulltext http://www.cell.com/article/S2666379122000350/abstract https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(22)00035-0"},"keyword":["Ad26.COV2.S","OA","Omicron","SARS-CoV-2","Variant of concern","antibody-dependent cellular cytotoxicity","breakthrough infection","fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","6GMFi5DCojy3jHY44"],"keywords":["ad26.cov2.s","oa","omicron","sars-cov-2","variant of concern","antibody-dependent cellular cytotoxicity","breakthrough infection","fund_ack","original"],"search_terms":["ad26","cov2","breakthrough","infections","induce","high","titers","neutralizing","antibodies","against","omicron","sars","cov","variants","concern","kitchin","richardson","van der mescht","motlou","mzindle","moyo-gwete","makhado","ayres","manamela","spencer","lambson","oosthuysen","kaldine","du pisanie","mennen","skelem","williams","ntusi","burgers","gray","bekker","boswell","rossouw","ueckermann","moore"],"title":"Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern","year":2022}